Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis

Company Overview

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS). In addition, Catalyst markets Ruzurgi® (amifampridine) tablets for pediatric LEMS patients. Beyond these approved therapies, Catalyst is advancing its pipeline programs that aim to extend its expertise in ion channel modulators to other rare and difficult-to-treat conditions.

Founded in 2002 and headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals went public on the Nasdaq Stock Market. The company focuses its operations on clinical development, regulatory strategy and commercialization activities within the United States. Catalyst continues to explore opportunities for international collaborations and licensing arrangements to broaden patient access to its rare disease portfolio.

Catalyst is led by President and Chief Executive Officer Patrick J. McEnany, who brings extensive experience in pharmaceutical product development and commercialization. Under his leadership, the company has strengthened its regulatory and commercial capabilities while advancing its pipeline toward future regulatory filings and potential approvals.

Key Stats

• Today's Range: $31.49 to $31.49
• 50-Day Range: $31.34 to $31.51
• 52-Week Range: $19.05 to $32.56
• Volume: N/A
• Average Volume: 2.62 million shs
• Market Capitalization: $3.86 billion
• P/E Ratio: 18.10
• Dividend Yield: N/A
• Price Target: $32.00
• Consensus Rating: Moderate Buy

Catalyst Pharmaceuticals Stock Analysis - MarketRank™

Catalyst Pharmaceuticals scored higher than 57% of companies evaluated by MarketBeat, and ranked 387th out of 914 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Catalyst Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 2 strong buy ratings, 1 buy rating, 6 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Catalyst Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Catalyst Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 16.67%

Earnings Growth

Earnings for Catalyst Pharmaceuticals are expected to grow by 16.67% in the coming year, from $2.64 to $3.08 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Catalyst Pharmaceuticals is 18.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.57.

Price to Earnings Ratio vs. Sector

The P/E ratio of Catalyst Pharmaceuticals is 18.10, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 269.18.

Price to Earnings Growth Ratio

Catalyst Pharmaceuticals has a PEG Ratio of 0.96. PEG Ratios around 1 indicate that a company is correctly valued.

Price to Book Value per Share Ratio

Catalyst Pharmaceuticals has a P/B Ratio of 4.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.31% of the float of Catalyst Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Catalyst Pharmaceuticals has a short interest ratio ("days to cover") of 0.11, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Catalyst Pharmaceuticals has recently decreased by 95.66%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Catalyst Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Catalyst Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for CPRX on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Catalyst Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.40% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

79.22% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/06/2025
• Today: 8/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CPRX
• CIK: 1369568
• Web: www.catalystpharma.com
• Phone: (305) 420-3200
• Fax: 305-529-0933
• Employees: 80
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Catalyst Pharmaceuticals: $32.00
• High Price Target: $33.00
• Low Price Target: $31.50
• Potential Upside/Downside: +1.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.74
• Trailing P/E Ratio: 18.10
• Forward P/E Ratio: 11.93
• P/E Growth: 0.96
• Net Income: $214.33 million
• Net Margins: 37.08%
• Pretax Margin: 49.66%
• Return on Equity: 35.76%
• Return on Assets: 31.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.10
• Quick Ratio: 6.84

Sales & Book Value

• Annual Sales: $596.96 million
• Price / Sales: 6.46
• Cash Flow: $2.92 per share
• Price / Cash Flow: 10.77
• Book Value: $7.76 per share
• Price / Book: 4.06

Miscellaneous

• Outstanding Shares: 122,420,000
• Free Float: 109,688,000
• Market Cap: $3.86 billion
• Optionable: Optionable
• Beta: 0.74